Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2005-10-11
2005-10-11
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093200, C424S093210, C435S320100, C435S455000, C514S04400A
Reexamination Certificate
active
06953575
ABSTRACT:
Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease.
REFERENCES:
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5667158 (1997-09-01), Bullock et al.
patent: 5720720 (1998-02-01), Laske et al.
patent: 6103226 (2000-08-01), Kang et al.
patent: 6180613 (2001-01-01), Kaplitt et al.
patent: 3841955 (1989-07-01), None
patent: 013 (1999-07-01), None
patent: WO 95/28493 (1995-10-01), None
patent: WO 95/34670 (1995-12-01), None
patent: WO 97/17458 (1997-05-01), None
patent: WO 98/00014 (1998-01-01), None
patent: WO 95/05864 (1998-03-01), None
Passini et al., 2002, Methods in Molecular Biology, Ed. W.C. Hessler, vol. 246, pp. 225-236.
Vite et al., 2003, Gene Therapy, 2003, vol. 10, p. 1874-1881.
Deonarain, M., 1998, Exp. Opin. Ther. Patents, vol. 8, No. 1, p. 53-69.
Eck et al., 1996, “Goodman & Gilma's The Pharamcological Basis of Therapeutics”, McGraw-Hill New York, p. 77-101.
Gorecki, D., 2001, Expert Opin. Emerging Drugs, vol. 6, No. 2, p. 187-198.
Mizuno et al., 1998, Jpn. J. cancer Res., vol. 89, p. 76-80.
Leff et al., 1997, Society for Neuroscience Abstracts, vol. 23, No. 1-2, pp. 541.
Okada et al., 1996, Gene therapy, vol. 3, No. 11, p. 957-964.
Zhu et al., 1996, Gene Therapy, vol. 3, No. 6, p. 472-476.
Bankiewicz et al., “Practical Aspects of the Development of ex Vivo and in Vivo Gene Therapy for Parkinson's Disease,”Experimental Neurology 144:147-156 (1997).
Bankiewicz et al., “Application of Gene Therapy for Parkinson's Disease: Nonhuman Primate Experience,”Advances in Pharmacology 42:801-806 (1998).
Brynes et al., “Immunological Instability of Persistent Adenovirus Vectors in the Brain: Peripheral Exposure to Vector Leads to Renewed Inflammation, Reduced Gene Expression, and Demyelination,”Journal of Neuroscience 16(9):3045-3055 (1996).
Carter, B.J., “Adeno-Associated Virus Vectors,”Current Opinion in Biotechnology 3:533-539 (1992).
Conrad et al., “Safety of Single-Dose Administration of an Adeno-Associated Virus (AAV)-CFTR Vector in the Primate Lung,”Gene Therapy 3:658-668 (1996).
During et al., “In Vivo Expression of Therapeutic Human Genes for Dopamine Production in the Caudates of MPTP-Treated Monkey's Using an AAV Vector,”Gene Therapy 5:820-827 (1998).
Eberling et al., “A Novel MPTP Primate Model of Parkinson's Disease: Neurochemical and Clinical Changes,”Brain Research 805:259-262 (1998).
Edge et al., “Total Synthesis of a Human Leukocyte Interferon Gene,”Nature 292:756-762 (1981).
Fan et al., “Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic L-Amino Acid Decarboxylase Genes Using Two Separate Adeno-Associated Virus Vectors,”Human Gene Therapy 9:2527-2535 (1998).
Flotte et al., “Stable In Vivo Expression of the Cystic Fibrosis Transmembrane Conductance Regulator With an Adeno-Associated Virus Vector,”Proc. Natl. Acad. Sci. USA 90:10613-10617 (1993).
Graham et al., “Characteristic of a Human Cell Line Transformed by DNA From Human Adenovirus Type 5,”J. Gen Virol. 36:59-72 (1977).
Herzog et al., “Long-Term Correction of Canine Hemophilia B by Gene Transfer of Blood Coagulation Factor IX Mediated By Adeno-Associated Viral Vector,”Nature Medicine 5:56-63 (1999).
Kaplitt et al., “Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain,”Nature Genetics 8:148-153 (1994).
Kaplitt et al., “Transfer and Expression of Potentially Therapeutic Genes into the Mammalian Central Nervous System In Vivo Using Adeno-Associated Viral Vectors,”Viral Vectors, Gene Therapy and Neuroscience Applications, Kaplitt and Loewy eds., 12:193-210, Academic Press, San Diego (1995).
Kass-Eisler et al., “The Impact of Developmental Stage, Route of Administration and the Immune System on Adenovirus-Mediated Gene Transfer,”Gene Therapy 1:395-402 (1994).
Kotin, R.M., “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,”Human Gene Therapy 5:793-801 (1994).
Kroll et al., “Increasing Volume of Distribution to the Brain with Interstitial Infusion: Dose, Rather Than Convection, Might be the Most Important Factor,”Neurosurgery 38(4):746-754 (1996).
Langston, J. William, “Mechanism of MPTP Toxicity: More Answers, More Questions,”Trends Pharmacol. Sci. 6:375-378 (1985).
Leff et al., “Long-Term Restoration of Striatal L-Aromatic Amino Acid Decarboxylase Activity Using Recombinant Adeno-Associated Viral Vector Gene Transfer in a Rodent Model of Parkinsons's Disease,” XP-000857456Neuroscience 92(1):185-196 (1999).
Lyden et al., “Effect of Ischemic Cerebral Volume Changes on Behavior,”Behavioral Brain Research 87:59-67 (1997).
Mandel et al., “Midbrain Injection of Recombinant Adeno-Associated Virus Encoding Rat Glial Cell Line-Derived Neurotrophic Factor Protects Nigral Neurons in a Progressive 6-Hydroxydopamine-Induced Degeneration Model of Parkinson's Disease in Rats,”Proc. Natl. Acad. Sci. USA 94:14083-14088 (1997).
Mandel et al., “Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in a Rat Model of Parkinson's Disease,”Journal of Neuroscience 18(11):4271-4284 (1998).
Matsushita, T. et al., “Adeno-Associated Virus Vectors Can Be Efficiently Produced Without Helper Virus,”Gene Therapy 5:938-945 (1998).
Mizuno et al., “Adeno-Associated Virus Vector Containing the Herpes Simplex Virus Thymidine Kinase Gene Causes Complete Regression of Intracerebrally Implanted Human Gliomas in Mice, in Conjunction With Ganciclovir Administration, ”Jpn. J. Cancer Res. 89:76-80 (1998).
Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,”Current Topics in Microbiol. and Immunol 158:97-129 (1992).
Okada et al., “Gene Therapy Against an Experimental Glioma Using Adeno-Associated Virus Vectors,”Gene Therapy 3:957-964 (1996).
Samulski et al., “A Recombinant Plasmid from Which an Infectious Adeno-Associated Virus Genome Can Be Excised In Vitro and Its Use to Study Viral Replication,”Journal of Virology 61(10):3096-3101 (1987).
Szczypka et al., “Viral Gene Delivery Selectively Restores Feeding and Prevents Lethality of Dopamine-Deficient Mice,”Neuron 22:167-178 (1999).
Yang et al., “Immune Responses to Viral Antigens Versus Transgene Product in the Elimination of Recombinant Adenovirus-Infected Hepatocytes In Vivo,”Gene Therapy 3:137-144 (1996).
Yang et al., “Cellular Immunity to Viral Antigens Limits E1-Deleted Adenoviruses for Gene Therapy,”Proc. Natl. Acad. Sci. USA 91:4407-4411 (1994).
Bankiewicz Krys
Cunningham Janet
Eberling Jamie L.
Avigen, Inc.
Chen Shin-Lin
Robins & Pasternak LLP
The Regents of the University of California
LandOfFree
Methods of treating central nervous system disorders using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating central nervous system disorders using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating central nervous system disorders using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487405